Capital Performance Advisors LLP Protalix Bio Therapeutics, Inc. Transaction History
Capital Performance Advisors LLP
- $449 Million
- Q1 2025
A detailed history of Capital Performance Advisors LLP transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Capital Performance Advisors LLP holds 25,976 shares of PLX stock, worth $41,821. This represents 0.01% of its overall portfolio holdings.
Number of Shares
25,976
Previous 25,976
-0.0%
Holding current value
$41,821
Previous $49,000
34.69%
% of portfolio
0.01%
Previous 0.02%
Shares
5 transactions
Others Institutions Holding PLX
# of Institutions
70Shares Held
8.27MCall Options Held
227KPut Options Held
54.5K-
Jim Simons Renaissance Technologies LLC | New York, Ny1.19MShares$1.91 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny963KShares$1.55 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA859KShares$1.38 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL685KShares$1.1 Million0.0% of portfolio
-
Marshall Wace, LLP London, X0615KShares$990,2860.0% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $80.1M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...